Human parvovirus B19 infection and antiphospholipid antibodies

Autoimmunity Reviews

Volumn 6, Issue 5, 2007, Pages 278-285

  von Landenberg, Philipp ^a   Lehmann, Hartwig W ^b   Modrow, Susanne ^c  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Antiphospholipid antibodies; Autoimmune reaction; Parvovirus B19 infection

Indexed keywords

AUTOANTIBODY; CAPSID PROTEIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; PHOSPHOLIPID ANTIBODY; VIRUS DNA; VIRUS PROTEIN;

ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASE; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ERYTHEMA INFECTIOSUM; HUMAN; IMMUNE RESPONSE; MOLECULAR MIMICRY; NONHUMAN; PARVOVIRUS; PATHOGENESIS; PERSISTENT VIRUS INFECTION; REVIEW; SEROLOGY; SEROPREVALENCE; VIRUS GENOME; VIRUS INFECTION; VIRUS TRANSMISSION;

ANTIBODIES, ANTIPHOSPHOLIPID; AUTOIMMUNE DISEASES; FEMALE; HUMANS; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 33947712105     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2006.09.006     Document Type: Review

References (36)

1. Cossart Y.E., Cant B., Field A.M., and Widdows D. Parvovirus-like particles in human sera. Lancet 1 (1975) 72-73
2. Anderson M.J., Jones S.E., Fisher-Hoch S.P., et al. The human parvovirus, the cause of erythema infectiosum (fifth disease)?. Lancet 1 (1983) 1378
3. Anderson M.J., Higgins P.G., Davis L.R., et al. Experimental parvoviral infection in humans. J Infect Dis 152 (1985) 257-265
4. Anderson M.J., Davis L.R., Hodgson, et al. Occurrence of infection with a parvovirus-like agent in children with sickle cell anaemia during a two-year period. J Clin Pathol 35 7 (1982) 744
5. Bültmann B.D., Klingel K., Sotlar K., Bock C.F., and Kandolf R. Parvovirus B19: a pathogen responsible for more than hematologic disorders. Virchows Arch 442 (2003) 8-17
6. Agbandje-McKenna M., Kajigaya S., McKenna R., Young N.S., and Rossmann M.G. The structure of human parvovirus B19 at 8 Å resolution. Virology 203 (1994) 106-115
7. Kawase M., Momoeda M., Young N.S., and Kajigaya S. Most of the VP1-unique region of parvovirus B19 is on the capsid surface. Virology 211 (1995) 359-366
8. Cohen B.J., and Buckley M.M. The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol 25 (1988) 151-153
9. Chorba T., Coccia P., Holman R.C., et al. The role of parvovirus B19 in aplastic crisis and erythema infectiosum. J Infect Dis 154 (1986) 383-393
10. Ozawa K., and Young N. Characterization of capsid and noncapsid proteins of B19 parvovirus propagated in human erythroid bone marrow cell cultures. J Virol 61 (1987) 2617-2630
11. Yaegashi N., Niinuma T., Chisaka H., et al. The incidence of, and factors leading to, parvovirus B19-related hydrops fetalis following maternal infection; report of 10 cases and meta-analysis. J Infect 37 (1998) 28-35
12. Blümel J., Schmidt I., Effenberger W., et al. Parvovirus B19 transmission by heat-treated clotting factor concentrates. Transfusion 42 (2002) 1473-1481
13. Saikawa T., Anderson S., Momoeda M., Kajigaya S., and Young N.S. Neutralizing linear epitopes of parvovirus B19 cluster in the VP1-unique and VP1-VP2-junction regions. J Virol 67 (1993) 3004-3009
14. von Poblotzki A., Gigler A., Lang B., Wolf H., and Modrow S. Antibodies to parvovirus NS1 protein in infected individuals. J Gen Virol 76 (1995) 519-527
15. Lehmann H.W., Kühner L., Beckenlehner K., et al. Chronic human parvovirus B19 infection in rheumatic diseases of childhood and adolescence. J Clin Virol 25 (2002) 135-143
16. Cherry J.D. Parvovirus infections in children and adults. Adv Pediatr 46 (1999) 245-269
17. Rogers B.B., Rogers Z.R., and Timmons C.F. Polymerase chain reaction amplification of archival material for parvovirus B19 in children with transient erythroblastopenia of childhood. Pediatr Pathol Lab Med 16 (1996) 471-478
18. Barah F., Vallely P.J., Chiswick M.L., Cleator G.M., and Kerr J.R. Human parvovirus B19 infection associated with acute meningoencephalitis. Lancet 358 (2001) 729-730
19. Kurtzman G.J., Ozawa K., Cohen B., Hanson G., Oseas R., and Young N.S. Chronic bone marrow failure due to persistent B19 parvovirus infection. N Engl J Med 317 (1987) 287-294
20. Enders M., Weidner A., Zoellner I., Searle K., and Enders G. Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases. Prenat Diagn 24 (2004) 513-518
21. Cassinotti P., Bas S., Siegl G., and Vischer T.L. Association between human parvovirus B19 infection and arthritis. Ann Rheum Dis 54 (1995) 498-500
22. Kerr J.R., Bracewell J., Laing I., et al. Chronic fatigue syndrome and arthralgia following parvovirus B19 infection. J Rheumatol 29 (2002) 595-602
23. Guillaume M.P., Hermanus N., and Peretz A. Unusual localisation of chronic arthropathy in lumbar facet joints after parvovirus B19 infection. Clin Rheumatol 21 (2002) 306-308
24. Naides S.J., Scharosch L.L., Foto F., and Howard E.J. Rheumatologic manifestations of human parvovirus B19 infection in adults. Initial two-year clinical experience. Arthritis Rheum 33 (1990) 1297-1309
25. Young N.S., Harrison M., Moore J., Mortimer P.P., and Humphries R.K. Direct demonstration of the human parvovirus in erythroid progenitor cells infected in vitro. J Clin Invest 74 (1984) 2024-2032
26. Fu Y., Ishii K.K., Munakata Y., Saitoh T., Kaku M., and Sasaki T. Regulation of tumor necrosis factor alpha promoter by human parvovirus B19 NS1 through activation of AP-1 and AP-2. J Virol 76 (2002) 5395-5403
27. Kerr J.R., Barah F., Mattey D.L., et al. Circulating tumour necrosis factor-alpha and interferon-gamma are detectable during acute and convalescent parvovirus B19 infection and are associated with prolonged and chronic fatigue. J Gen Virol 82 (2001) 3011-3019
28. Von Landenberg P., Lehmann H.W., Knoll A., Dorsch S., and Modrow S. Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection. Arthritis Rheum 48 (2003) 1939-1947
29. Cervera R., Piette J.C., Font J., et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 46 (2002) 1019-1027
30. Loizou S., Cazabon J.K., Walport M.J., Tait D., and So A.K. Similarities of specificity and cofactor dependence in serum antiphospholipid antibodies from patients with human parvovirus B19 infection and from those with systemic lupus erythematosus. Arthritis Rheum 40 (1997) 103-108
31. Lunardi C., Tiso M., Borgato L., et al. Chronic parvovirus B19 infection induces the production of anti-virus antibodies with autoantigen binding properties. Eur J Immunol 28 (1998) 936-948
32. Sekine T., Kato T., Masuko-Hongo K., et al. Type II collagen is a target antigen of clonally expanded T cells in the synovium of patients with rheumatoid arthritis. Ann Rheum Dis 58 (1999) 446-450
33. Serra C.R.B., Rodrigues S.H., Silva N.P., Sztajnbok F.R., and Andrade L.E.C. Clinical significance of anticardiolipin antibodies in juvenile idiopathic arthritis. Clin Exp Rheumatol 17 (1999) 375-380
34. Reitblat T., Drogenikov T., Sigalov I., Oren S., and London D. Transient anticardiolipin antibody syndrome in a patient with parvovirus B19 infection. Am J Med 109 (2000) 512
35. Blank M., Krause I., Fridkin M., et al. Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. Clin Invest 109 (2002) 797-804
36. Takasawa N., Munakata Y., Ishii K.K., et al. Human parvovirus B19 transgenic mice become susceptible to polyarthritis. J Immunol 173 (2004) 4675-4683